Paroxysmal Nocturnal Hemoglobinuria News and Research

RSS
FDA approves Alexion's Rhode Island manufacturing facility as commercial supply source for Soliris

FDA approves Alexion's Rhode Island manufacturing facility as commercial supply source for Soliris

Taligen Therapeutics to highlight three pipeline candidates at XXIII ICW

Taligen Therapeutics to highlight three pipeline candidates at XXIII ICW

Alexion second-quarter non-GAAP net income increases 56% to $36.9 million

Alexion second-quarter non-GAAP net income increases 56% to $36.9 million

Alexion's Soliris may benefit patients with thrombotic microangiopathy from uncontrolled complement activation

Alexion's Soliris may benefit patients with thrombotic microangiopathy from uncontrolled complement activation

New research evaluating substantial disease burden of PNH presented at European Hematology Association

New research evaluating substantial disease burden of PNH presented at European Hematology Association

Alexion Pharmaceuticals reports total revenues of $117.6M from net product sales of Soliris

Alexion Pharmaceuticals reports total revenues of $117.6M from net product sales of Soliris

Alexion Pharmaceuticals' Soliris NDA for PNH receives approval in Japan

Alexion Pharmaceuticals' Soliris NDA for PNH receives approval in Japan

Rare Disease Day 2010: Alexion Pharmaceuticals joins NORD and EURORDIS to raise awareness

Rare Disease Day 2010: Alexion Pharmaceuticals joins NORD and EURORDIS to raise awareness

Alexion Pharmaceuticals announces financial results for quarter and year ended December 31, 2009

Alexion Pharmaceuticals announces financial results for quarter and year ended December 31, 2009

New data shows patients with Type II PNH cells experience platelet consumption and increased thrombosis risk

New data shows patients with Type II PNH cells experience platelet consumption and increased thrombosis risk

Data on Alexion Pharmaceuticals' Soliris to be presented at the ASH meeting

Data on Alexion Pharmaceuticals' Soliris to be presented at the ASH meeting

Alexion Pharmaceuticals reports increased revenues of 11% in third quarter 2009

Alexion Pharmaceuticals reports increased revenues of 11% in third quarter 2009

Real Americans share experiences, common need for patient-centric reform

Real Americans share experiences, common need for patient-centric reform

Soliris (Eculizumab) granted orphan drug designation in Europe and U.S. for atypical hemolytic uremic syndrome

Soliris (Eculizumab) granted orphan drug designation in Europe and U.S. for atypical hemolytic uremic syndrome

Scientists edit genes in human stem cells

Scientists edit genes in human stem cells

PDL BioPharma and Alexion Pharmaceuticals resolve patent dispute

PDL BioPharma and Alexion Pharmaceuticals resolve patent dispute

FDA approves Soliris (eculizumab), first treatment for paroxysmal nocturnal hemoglobinuria

FDA approves Soliris (eculizumab), first treatment for paroxysmal nocturnal hemoglobinuria

Researchers have identified a new clinical syndrome

Researchers have identified a new clinical syndrome